Prof. Ulrich Jäger | ICML 2017 | Durvalumab with R-CHOP or lenalidomide in DLBCL

By Anne Villeneuve

Featured

Ulrich Jäger

Jun 16, 2017

Durvalumab with R-CHOP or lenalidomide in DLBCL

More about...

Aggressive B-cell lymphomas Diffuse large B-cell lymphoma Durvalumab ICML 2017

EHA 2019 | How will the sequencing of treatments for DLBCL change in the future?

Ulrich Jäger from the Medical University of Vienna, Vienna, AT, discusses how to decide what treatments to use, and when, for patients with relapsed/refractory (R/R)...

Jun 20, 2019

EHA 2019 | How will the sequencing of treatments for DLBCL change in the future?

Ulrich Jäger from the Medical University of Vienna, Vienna, AT, discusses how to decide what treatments to use, and...

Jun 20, 2019

Ulrich Jäger | EHA 2018 | What are the potential causes of aggressive B-cell lymphomas under JAK1/2 inhibition?

Ulrich Jäger on the potential causes of agressive B-cell lymphomas under JAK1/2 inhibition, EHA 2018

Jun 18, 2018

Ulrich Jäger | EHA 2018 | What are the potential causes of aggressive B-cell lymphomas under JAK1/2 inhibition?

Ulrich Jäger on the potential causes of agressive B-cell lymphomas under JAK1/2...

Jun 18, 2018

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Prof. Ulrich Jäger | ICML 2017 | Durvalumab with R-CHOP or lenalidomide in DLBCL

By Anne Villeneuve

Featured

Ulrich Jäger

Jun 16, 2017

More about...

Related articles

Jun 20, 2019

Jun 20, 2019

Jun 18, 2018

Jun 18, 2018

Newsletter